For older adults with type 2 diabetes, GLP-1 RA use is associated with nonarteritic anterior ischemic optic neuropathy.

The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly , ...

In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers. Download the app ...

I’ve had a very eventful year. At the beginning of 2025, my long-term relationship ended, and after a few months, I decided ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...